Intensity Therapeutics, Inc. (INTS)
Automate Your Wheel Strategy on INTS
With Tiblio's Option Bot, you can configure your own wheel strategy including INTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INTS
- Rev/Share 0.0006
- Book/Share 0.1678
- PB 2.3244
- Debt/Equity 0.0163
- CurrentRatio 3.5967
- ROIC -1.6396
- MktCap 18388085.0
- FreeCF/Share -0.2207
- PFCF -1.9356
- PE -1.4304
- Debt/Assets 0.0123
- DivYield 0
- ROE -3.7086
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Intensity Therapeutics, Inc. ( INTS ) Discusses eBioMedicine Paper Study Results and Underlying Technology October 31, 2025 9:00 AM EDT Company Participants Lewis Bender - Founder, President, CEO & Chairman of the Board Conference Call Participants Jacob Stephen Thomas Anthony El-Khoueiry Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Intensity Therapeutics Discovery Lancet Discovery Group eBioMedicine Publication Webinar. [Operator Instructions] Please also note today's event is being recorded.
Read More
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland SHELTON, Conn. and BERN, Switzerland , May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research SAKK ("SAKK"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that the European Medicines Agency ("EMA") has …
Read More
About Intensity Therapeutics, Inc. (INTS)
- IPO Date 2023-06-30
- Website https://www.intensitytherapeutics.com
- Industry Biotechnology
- CEO Lewis H. Bender
- Employees 5